


BIOGNOSYS
NEXT GENERATION PROTEOMICS

Transformative insights from discovery to clinic



We believe we can dramatically improve human health by deciphering biological complexity.


- ❖ **Next-generation proteomics is revolutionizing life sciences and targeted therapies**
- ❖ **Industry-leading depth and scalability that unlocks full, unbiased access to the functional proteome**
- ❖ **Heritage of invention and innovation backed by a world-class scientific and entrepreneurial leadership**

At the Vanguard of Breakthrough

Huge opportunity for applying deep proteomics data and insights

Proteomics decodes the realities of a disease


Proteomics bridges the static information provided by genomics of “what could be,” with the context to understand what’s actually happening, *right now* so disease can be treated.



Proteomics addresses impediments to precision medicine

Proteomics' greatest potential lies in the targeted drug space, where the vast majority of druggable targets are unaccounted for, and matching the right patients with the right drug targets is challenging.

Death of novel drug targets




Poor understanding of patient stratification



Powering precision medicine into reality

Biognosys can decode proteomics insights that will transform the development of new targeted therapies.

Deep insights for drug-hunting




Biognosys discovered novel protein targets of an exploratory compound using proprietary structural proteomics technology

(Data published in peer-reviewed journal in collaboration with AstraZeneca)



Broad data to decode disease

Biognosys identified a novel proteomic signature that predicts clinical outcome to immunotherapy
(Data presented at ESMO 2020 in collaboration with Institut Curie)



Proteomics transforms clinical decision making

“

Recent advances in proteomics help us explore complex diseases to identify novel targets for intervention. In NASH, the need is so great, the population so diverse and the timing is perfect.

”

Julia Wattacheril, MD MPH

Nonalcoholic Fatty Liver Disease Program Director
Columbia University Irving Medical Center



“


Different subsets of pancreatic cancer patients may be more likely to respond to chemo and PD-1 versus chemo and CD40. Our findings provide clues on how to best identify these patients.

”

Theresa LaVallee, PhD

Former Vice President, Translational Medicine and Regulatory Affairs
Parker Institute for Cancer Immunotherapy




The background of the slide is a 3D visualization of protein structures. The proteins are rendered in a light blue, semi-transparent, surface-like style, showing their complex, irregular shapes. They are scattered across the frame, with some appearing larger and more detailed than others, creating a sense of depth and scientific focus.

Not All Proteomics Are Created Equal


Actionable insights born from an unbiased approach to discovery

The road to gold standard


Gold standard technology must check all of these boxes



DEEP COVERAGE




**UNBIASED,
UNIVERSAL ANALYSIS**



**MULTI-DIMENSIONAL
INSIGHTS**


Biognosys leads with the deepest proteomics technology

We can measure more proteins than anyone else with >13,800 proteins in cells and tissues and >4,200 proteins in plasma.




Unbiased, universal detection without limits

Affinity-based methods have a limited view



Biognosys can see it all

 **BIOGNOSYS**
NEXT GENERATION PROTEOMICS




Biognosys' unique technology – even among other mass-spec approaches – is not influenced by what we know, but instead analyzes and reveals the whole proteome in any sample type from any species.


Our view is as multi-dimensional as cellular functions

Affinity reagents cover only small epitope sites per protein

APOE




TTR




 Covered sequence (extrapolation)

Biognosys covers many more parts of the protein and its proteoforms

APOE



TTR




 Covered sequence
 Covered regions of known genetic variation


We can also unravel other aspects of the proteome



PROTEIN QUANTIFICATION



PROTEIN STRUCTURE



POST-TRANSLATIONAL MODIFICATIONS



PROTEIN INTERACTIONS

Biognosys Leadership in Proteomics

Next-generation proteomics solutions built on heritage of invention and innovation

Biognosys by the numbers

Global HQ in Zurich, Switzerland



US Offices in Cambridge, MA

> 13

Years of proteomics innovation

> 1 Billion

Data points generated each year

> 800

Clients; 19 of the top 20 pharmaceutical companies

> 2,000

Scientific publications

> 1,600

Samples per day – Largest high-end facility in the world

> 20

Granted patents

Our Collaborators

Strategic Collaborators



Scientific Collaborators



We make the proteome accessible by covering the widest range of researchers' needs

Mission

We enable life science researchers and drug hunters to unlock true discoveries by looking at the proteome from every angle. We push the boundaries of what is possible with our proteomics solutions to improve human health.

Services

TRUE DISCOVERY™

BIOFLUID
BIOMARKER
DISCOVERY

TISSUE
BIOMARKER
DISCOVERY

DRUG
TARGET
DECONVOLUTION

DRUG
TARGET
VALIDATION

MECHANISM
OF ACTION
STUDIES

PHOSPHO
PROTEOME
PROFILING

IMMUNO
PEPTIDOME
PROFILING

TRUE TARGET™

TRUE SIGNATURE™

CLINICAL
BIOMARKER
PANELS

PHARMACO
DYNAMIC
BIOMARKERS

State-of-the-art **high-throughput facility**, the largest of its kind in the world

Software

Data-Independent
Acquisition (DIA)



Data-Dependent
Acquisition (DDA)



AI-empowered software solutions for
streamlined data analytics

Targeted
Proteomics



Quality Control



Kits

Peptide Kits for Quantification



Peptide Kits for Quality Control



Sample Preparation Kits



Ready-to-use kits for
absolute quantification

Biognosys' solutions are used by clients across all phases from research to clinical trials

Enabling researchers to accelerate and de-risk drug discovery and development.



Discovery Biology



Preclinical Studies



Early & Late Clinical Studies



Population health screening



Target Deconvolution



Animal Model Profiling



Blood



Patients Stratification



Mechanism of Action



Translational Biomarker Discovery



CSF



Disease Insights Generation



Target Validation, Novel Target Discovery



Validation of Protein Expression



Urine



Novel Drug Target Discovery



Disease Biology Profiling



Toxicity Profiling



Tissues




Identification of Prognostic and Predictive Biomarkers

Biognosys is well-cited in the scientific literature

Co-authored multiple publications in high-impact, peer-reviewed journals.



Publications Mentioning Biognosys, their Technology & Tools (Status 12/2021)



Experienced executive management supported by leading proteomics experts

Executive Management

[Bios](#)



Oliver Rinner, PhD
Co-founder, CEO



Lukas Reiter, PhD
Chief Technology Officer



Kristina Beeler, PhD
Chief Business Officer



Karel Novy, PhD
Chief Operating Officer



Lidia Novak, CFA
Chief Financial Officer

Scientific Advisory Board



Prof. Ruedi Aebersold
Co-founder, ETH Zurich



Prof. Paula Picotti
ETH Zurich



Prof. Johan Malmstroem
Co-founder, Lund University

TRANSFORMATIVE INSIGHTS FROM DISCOVERY TO CLINIC



www.biognosys.com